Skip to main content
. Author manuscript; available in PMC: 2014 Jun 19.
Published in final edited form as: Lancet Neurol. 2012 Feb 3;11(3):241–249. doi: 10.1016/S1474-4422(12)70015-7

Figure 3. Kaplan-Meier plots for ARIA-E by bapineuzumab dose (a), number of APOE ε4 alleles (b), and presence of small hemosiderin deposits at baseline (c).

Figure 3

Figure 3

Figure 3

Increasing dose and number of APOE ε4 alleles were associated with an increased risk of ARIA-E over time. In the accompanying graphs, an increased risk of ARIA-E may be readily visualized by the decrease in the Kaplan-Meier survivor function after the first two doses, based on MRI readings performed 6 weeks after the baseline and month 3 infusions, in both subjects treated with the highest dose (2 mg/kg) and in APOE ε4 homozygotes. No increased risk was apparent for the presence small hemosiderin deposits at baseline.